Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2018, provides an overview of the Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline landscape.
Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headaches, shortness of breath, dehydration and infection. Treatment includes NSAIDs, acetaminophen, blood transfusion and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 3, 4, 1, 1, 1 and 1 respectively.
Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Overview
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Companies Involved in Therapeutics Development
Asklepion Pharmaceuticals LLC
AstraZeneca Plc
Bristol-Myers Squibb Co
Gilead Sciences Inc
Global Blood Therapeutics Inc
Modus Therapeutics AB
Novartis AG
NuvOx Pharma LLC
Pfizer Inc
Prolong Pharmaceuticals LLC
Seattle Genetics Inc
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Drug Profiles
apixaban - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crizanlizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inclacumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
L-Citrulline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVX-508 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
regadenoson - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rivipansel sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sanguinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sevuparin sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SGN-2FF - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ticagrelor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Dormant Projects
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Discontinued Products
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Product Development Milestones
Featured News & Press Releases
Jan 09, 2018: Prolong Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
Dec 13, 2017: Prolong Pharma Announces Completion of Enrollment in Phase II Study of SANGUINATE in the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis in an Ambulatory Setting
Nov 08, 2017: Prolong Pharmaceuticals to Present New Research on SANGUINATE, an Investigational Treatment Under Evaluation for Vaso-Occlusive Crisis in Patients with Sickle Cell Disease, at ASH Annual Meeting
Feb 01, 2017: A multiple drug approach to preventing sickle cell crisis
Oct 29, 2015: GlycoMimetics Announces Initiation of First Clinical Trial Evaluating Subcutaneous Administration of Rivipansel
Oct 29, 2015: Halozyme Announces First Clinical Dosing Of Pfizer's Rivipansel Using Enhanze Technology
Jun 23, 2015: GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel
Apr 07, 2015: GlycoMimetics Provides Update on Pfizer's Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015
Nov 06, 2014: GlycoMimetics Sickle Cell Data to Be Highlighted at 56th ASH Annual Meeting
Sep 26, 2014: GlycoMimetics Announces a Delay in the Initiation of the Phase 3 Trial With Rivipansel
Jul 01, 2014: GlycoMimetics Announces Agreement with FDA on Special Protocol Assessment for Phase 3 Clinical Trial of Rivipansel (GMI-1070)
May 21, 2014: GlycoMimetics Receives $15 Million Payment from Pfizer in Connection with Planned Initiation of Phase 3 Trial
Sep 13, 2013: GlycoMimetics Announces EMA’s Granting of Orphan Drug Status in European Union for GMI-1070 in Sickle Cell Disease
Aug 19, 2013: Selexys Pharmaceuticals Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients with Pain Crises
Jan 17, 2013: GlycoMimetics Completes Enrollment In Phase II Sickle Cell Disease Study With Lead Drug Candidate GMI-1070
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Asklepion Pharmaceuticals LLC, H2 2018
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by AstraZeneca Plc, H2 2018
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Bristol-Myers Squibb Co, H2 2018
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Gilead Sciences Inc, H2 2018
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Global Blood Therapeutics Inc, H2 2018
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Modus Therapeutics AB, H2 2018
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Novartis AG, H2 2018
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by NuvOx Pharma LLC, H2 2018
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Pfizer Inc, H2 2018
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Prolong Pharmaceuticals LLC, H2 2018
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Seattle Genetics Inc, H2 2018
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Dormant Projects, H2 2018
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
